Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPAS: Abacavir vs Tenofovir on Coagulation in HIV
NCT02093585Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2014
- Primary completion
- Apr 2016
- Countries
- 1
- Drugs
- abacavir
- Conditions
- human immunodeficiency virus type 1 infection (HIV-1)
01
Overview
Phase 4, randomised, open-label trial of abacavir in human immunodeficiency virus type 1 infection (HIV-1). Started Jan 2014; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
Some but not all observational studies have found that current exposure to abacavir is associated with increased risk of cardiovascular events such as myocardial infarction, stroke and cardiovascular death. This study aim to investigate possible adverse effect of abacavir on platelet reactivity, coagulation and endothelial activation in HIV-1 infected patients. The study is an open-labeled cross-over trial, where patients receiving antiretroviral therapy containing abacavir switch treatment to a regimen containing tenofovir and vice versa for a period of 90 days.
Beyond the preview
Go deeper on NCT02093585.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02093585.